NCT01850121

Remicade in the Treatment of Patients With Active Ankylosing Spondylitis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 19 (actual)
• Sponsor: Göteborg University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study was to evaluate the efficacy of infliximab (IFX) treatment, 5 mg/kg every 6 weeks, in patients with active ankylosing spondylitis (AS) and to determine whether IFX dose reduction and interval extension, 3 mg/kg every 8 weeks during the second year sustained the treatment effect. The study was started in 2003 an finished in 2008.

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	Infliximab	5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.

Timeline

• Start date: 2003-01-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2013-05-09
• Last updated: 2016-08-09

Locations

1 site across 1 country: Sweden